When should I start treatment for HER2-Low Breast Cancer vs watchful waiting

HER2-Low Breast Cancer: Treatment Timing Decisions

This is an important question that sits at the intersection of emerging science and personalized medicine. Let me walk you through how doctors think about this decision and what factors matter.

How Doctors Approach HER2-Low Breast Cancer

HER2-low breast cancer is a relatively newly recognized category—it's different from HER2-negative (completely negative) and HER2-positive (clearly positive). According to the CancerPatientLab webinars featuring Dr. [removed] Lopez-Correa, an MD/PhD who navigated her own HER2-low breast cancer diagnosis, this distinction is clinically important because it opens up specific treatment options that weren't available before.

The key clinical reasoning:

• HER2-low status can be detected through genomic sequencing, which may pick up small amplifications that traditional testing (like IHC staining) might classify as borderline
• The presence of HER2-low, combined with OTHER tumor characteristics, helps determine urgency of treatment

Factors That Influence the Treatment vs. Watchful Waiting Decision

Rather than HER2-low status alone driving the decision, doctors typically consider a combination of factors:

1. Proliferation Rate (Ki-67)

This measures how fast your cancer cells are dividing. In Dr. [removed]-Correa's case, her Ki-67 was 28%, which is considered high and was a critical factor in her oncologist recommending CDK4/6 inhibitors (a type of targeted therapy). A lower Ki-67 might support a more cautious approach.

2. Hormone Receptor Status

• ER/PR positive (estrogen and progesterone receptor positive) cancers often grow more slowly and may be candidates for hormone therapy first
• This can sometimes allow for observation before adding other treatments

3. Stage and Evidence of Disease

• Early-stage disease with no evidence of spread may warrant different timing than metastatic disease
• Liquid biopsy tests (like Signatera) can help detect circulating tumor DNA, which may influence surveillance intensity

4. Your Overall Health and Life Circumstances

Dr. [removed]-Correa emphasized that patient preference and quality of life matter. Some patients prioritize:

• Avoiding side effects early on
• Maintaining normal activities
• Waiting for clearer evidence of progression

The "Active Surveillance" Concept

An important framework emerging in breast cancer is active surveillance—essentially watchful waiting with close monitoring. According to the webinar discussions:

• Active surveillance means monitoring your disease closely WITHOUT immediate treatment
• This requires frequent imaging (CT scans, breast exams) and possibly blood tests
• If your tumor burden (measured by doubling time) remains stable, you may not need treatment yet
• If progression is detected, treatment can be started promptly

The rationale: Just because we CAN detect something doesn't automatically mean we should treat it immediately. As discussed in the webinars, earlier detection doesn't always lead to better outcomes—but having multiple treatment options available (which we do today) makes timing more strategic.

Liquid Biopsy and Minimal Residual Disease (MRD)

Tests like Signatera measure circulating tumor DNA in your blood. According to the CancerPatientLab discussions:

• A positive Signatera suggests higher recurrence risk and might prompt earlier treatment or increased imaging
• A negative Signatera might support a more conservative approach
• However, these tests are still evolving—they're not yet standard of care for all patients, and a positive result doesn't automatically mean you must start treatment immediately

Important caveat: As noted in the webinars, liquid biopsy tests are still in the "promise" stage rather than fully proven to improve survival outcomes. Your doctor will help interpret what the result means for YOUR specific situation.

Questions to Ask Your Oncologist

To help guide this decision with your care team:

1. "What is my Ki-67, and how does it influence the timing of treatment?"

2. "Given my stage and hormone receptor status, what does the evidence suggest about starting treatment now versus monitoring first?"

3. "Would a liquid biopsy test (like Signatera) help inform this decision, and would the results change your recommendation?"

4. "What would active surveillance look like for me—how often would I have imaging and blood tests?"

5. "At what point would you recommend starting treatment if we choose to monitor first? What signs would trigger that?"

6. "Are there clinical trials available that might be appropriate for my HER2-low status?"

The Bottom Line

According to the medical discussions in the CancerPatientLab webinars, there's no one-size-fits-all answer. Your oncologist will weigh:

• Your tumor's biological characteristics (proliferation rate, hormone sensitivity, HER2-low status)
• Stage of disease
• Results from any biomarker testing
• Your preferences and quality of life priorities

Dr. [removed]-Correa's experience illustrates this well: her doctors recommended CDK4/6 inhibitors based on the combination of HER2-low status, high Ki-67, and other factors—but this was a personalized decision based on her complete clinical picture.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.